The GlaxoSmithKline share price won’t stop rising. Is there still time to buy?

Pharmaceutical giant GlaxoSmithKline plc (LON:GSK) reveals its latest set of quarterly numbers. Paul Summers takes a closer look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Shares in FTSE 100 pharmaceutical firm GlaxoSmithKline (LSE: GSK) were on the front foot again this afternoon, building on the positive momentum shown by the stock since the beginning of 2019. The reason? A solid set of Q3 numbers, released at noon. Here’s what you need to know.

Further good progress

Group sales over this quarter came in a touch under £9.4bn — a rise of 16%. This brings the total turnover for the first nine months to £24.9bn — 7% higher than over the same period in 2018 once currency fluctuations are considered.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Positively, all three of Glaxo’s businesses registered solid growth. While the majority of sales (£4.5bn) continue to be generated by its pharmaceuticals business with respiratory bringing in £806m (+25%) and HIV hitting £1.3bn (+5%)  it’s the other parts of Glaxo that will be grabbing the headlines today.

Sales at its consumer healthcare and vaccines businesses soared by 30% and 20% respectively. The £2.5bn generated by the former was largely the result of the company’s recent joint venture with US giant Pfizer (a new business that will eventually become a separate listed entity). A good portion of the latter’s £2.3bn can be attributed to an 87% jump in sales of its Shingrix shingles vaccine over the period.  

All told, adjusted operating profit grew 10% over the period to £2.8bn and 9% over the first nine months to £7.1bn, adding substance to CEO Emma Walmsley’s claim that the company had “made further good progress” over the quarter

But there was more good news. Glaxo also announced today that it would be revising its guidance for the full year, with flat adjusted earnings per share now expected as a result of recent performance, increased investment and lower tax rates. This is clearly a great improvement on the prediction of -3% to -5% made back in July

Dividend hero

All things considered, I really can’t see anything in today’s release for current investors to complain or worry about. 

But let’s not kid ourselves here: the vast majority of people holding Glaxo probably aren’t that bothered about performance over a single three-month period. They’re in it for the income its shares generate, even if the annual payout hasn’t budged for years.

And I don’t blame them, particularly as the extent to which these payouts are covered by profit is now starting to look far more healthy. Before markets opened this morning, the predicted 80p per share cash return translated to a yield of 4.6%.  

What’s perhaps more surprising is that Glaxo’s shares still look reasonably priced, despite hitting heights not seen in almost 20 years and the firm boasting an encouraging pipeline with “advanced assets in Respiratory, HIV and […] Oncology“.

At 15 times earnings for the current financial year, they’re still far below the company’s 5-year average price-to-earnings (P/E) ratio of 23 and a lot cheaper than the 26 times earnings prospective buyers of FTSE 100 peer Astrazeneca are currently being asked to cough up.

The above, when combined with the defensive qualities that pharmaceuticals offer, make it a great company to own in times of trouble. It will never be completely immune to general stock market shudders but it certainly shouldn’t keep you awake at night.

With a general election now in the calendar and no telling where we might be at the beginning of 2020, Glaxo looks a strong buy to me.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

£10,000 invested in BT shares 10 years ago is now worth this much

It's painful to remember that BT shares reached over £10 at the peak of the dot com bubble in 1999.…

Read more »

Close-up Of A Piggybank With Eyeglasses And Calculator On Desk
Investing Articles

Is now the time to buy bank shares?

Our writer considers whether bank shares could be a bargain buy for his portfolio right now -- or a potential…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

After steep falls, are Royal Mail shares a steal?

Royal Mail shares have more than halved since peaking a year ago. After months of steep falls, this popular stock…

Read more »

Young Woman Drives Car With Dog in Back Seat
Investing Articles

Dirt-cheap, 1 of my best stocks to buy also pays an above-average dividend!

This Fool has decided to buy the shares on his best stocks to buy now list with the shares looking…

Read more »

Light bulb with growing tree.
Investing Articles

The AFC share price just tanked! Is now the time to buy?

The AFC share price fell nearly 10% on Wednesday after the H1 revenue announcement. So, should I add this stock…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

These shares have been growing dividends for decades. I’d buy!

Our writer considers the merits for his portfolio of buying two shares with a track record of growing dividends.

Read more »

Close-up of British bank notes
Investing Articles

Is the M&G dividend yield heading to 10%?

As the M&G dividend yield heads towards double digits, out writer explains why he is considering buying more of the…

Read more »

man in shirt using computer and smiling while working in the office
Investing Articles

3 top dividend shares to buy now

With weakness in the markets, I reckon it's a good time to search for top dividend shares to buy now.

Read more »